Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCigna Arikayce Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentCignaPolicy IP0383

    Antibiotics (Inhaled) - Arikayce

    Customize your policy alerts

    Sign up for Cigna Policy IP0383 alerts

    Get alerted when Policy IP0383 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and medical-necessity coverage for Arikayce in adults with refractory MAC lung disease and for cystic fibrosis-associated Pseudomonas aeruginosa infection, subject to specified clinical and specialist-treatment criteria.

    Policy Summary
    PayerCigna
    PolicyAntibiotics (Inhaled) - Arikayce
    Policy CodePolicy IP0383
    Change TypeMaterial clinical criteria revision
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and submit documentation supporting the applicable clinical criteria before requesting coverage.
    SourceLink
    POLICY UPDATE CHANGES

    For initial MAC lung disease therapy, the policy replaced the refractory-disease wording with requirements for completion of at least 6 consecutive months of background multidrug therapy and a positive MAC sputum culture.

    The policy title was updated from Amikacin Liposome to Antibiotics (Inhaled) - Arikayce Prior Authorization Policy.

    1 yearInitial MAC approval
    ≥6 monthsBackground therapy required
    18+Minimum age
    12 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Post-conversion therapy
    2Covered indication groups
    Not coveredOther uses

    Covered Uses and Limitations

    FDA-approved indication: MAC lung disease

    Arikayce is medically necessary for MAC lung disease when ONE of the following pathways is met:

    MAC lung disease coverage pathways

    • Initial therapy

      • Initial MAC requirements

        • Patient is at least 18 years of age.
        • Patient has completed at least 6 consecutive months of a background multidrug regimen.≥ 6 consecutive months

          A typical regimen includes a macrolide, ethambutol, and a rifamycin.

        • Patient has a positive sputum culture for Mycobacterium avium complex.

          Any positive sputum culture obtained after completion of at least 6 consecutive months of a background multidrug regimen fulfills this criterion.

        • The Mycobacterium avium complex isolate is susceptible to amikacin according to the laboratory report.
        • Arikayce will be used in conjunction with a background multidrug regimen.
        • Arikayce is prescribed by a pulmonologist, infectious diseases physician, or physician who specializes in the treatment of Mycobacterium avium complex lung infections.
    • Currently receiving Arikayce

      • Arikayce will be used in conjunction with a background multidrug regimen.
      • ONE sputum-culture status criterion

        • Patient has not achieved negative sputum cultures for Mycobacterium avium complex.Approve for 1 year
        • Patient has achieved negative sputum cultures for Mycobacterium avium complex for less than 12 months.Approve for 1 year total

          Approve enough Arikayce to complete 12 months of therapy following a negative sputum culture.

    Other use with supportive evidence: cystic fibrosis

    Approve for 1 year when ALL of the following are met:

    Cystic fibrosis

    • Patient has Pseudomonas aeruginosa in an airway culture, such as a sputum culture, oropharyngeal culture, or bronchoalveolar lavage culture.
    • Arikayce is prescribed by or in consultation with a pulmonologist or a physician who specializes in the treatment of cystic fibrosis.

    Arikayce is not recommended for non-refractory MAC lung disease. It has been studied in patients with refractory MAC lung disease who have not achieved culture negativity after at least 6 months of background multidrug treatment.

    Arikayce used for any purpose other than the covered MAC lung disease and cystic fibrosis with Pseudomonas aeruginosa indications is considered not medically necessary.

    Coverage Thresholds

    Background multidrug therapy duration
    Minimum completed durationAt least 6 consecutive months of a background multidrug regimen
    Typical regimen componentsA macrolide, ethambutol, and a rifamycin
    Related culture requirementA positive MAC sputum culture obtained after completion of at least 6 consecutive months fulfills the criterion
    Minimum age for initial MAC therapy
    Minimum ageAt least 18 years
    Initial approval durationApprove for 1 year when all initial MAC therapy criteria are met
    Specialist prescriber

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for benefit coverage of Arikayce. Initial approval requires the drug to be prescribed by, or in consultation with, a physician who specializes in the condition being treated because of the specialized evaluation, diagnosis, monitoring, and long-term efficacy requirements.

    Documentation Required

    Initial MAC Documentation

    For initial therapy for Mycobacterium avium complex (MAC) lung disease, document that the patient meets all applicable requirements before requesting Arikayce.

    • Patient is at least 18 years of age.
    • Patient completed at least 6 consecutive months of a background multidrug regimen, typically including a macrolide, ethambutol, and a rifamycin.
    • A sputum culture is positive for Mycobacterium avium complex; any positive culture obtained after completion of at least 6 consecutive months of background therapy meets this requirement.

    Therapy Overview

    Arikayce is an amikacin liposome suspension for oral inhalation used as part of a combination antibacterial regimen. The policy addresses treatment of adults with MAC lung disease who have limited or no alternative treatment options and who do not achieve negative sputum cultures after at least 6 consecutive months of background multidrug therapy.

    Clinical Definitions

    Culture conversion
    Required number of negative culturesThree consecutive negative sputum cultures
    Testing intervalMonthly sputum cultures
    TimingCulture conversion must be achieved by Month 6
    Background multidrug regimen
    MacrolideAzithromycin or clarithromycin
    EthambutolEthambutol
    RifamycinRifampin or rifabutin

    Initial Therapy

    Initial MAC lung disease therapy

    Approve for 1 year when ALL of the following are met:

    Initial MAC therapy

    • Patient is at least 18 years of age.≥ 18 years
    • Patient has completed at least 6 consecutive months of a background multidrug regimen.≥ 6 consecutive months

      A typical regimen includes a macrolide, ethambutol, and a rifamycin.

    • Patient has a positive sputum culture for Mycobacterium avium complex.

      Any positive sputum culture obtained after completion of at least 6 consecutive months of a background multidrug regimen fulfills this criterion.

    Continuation Therapy

    Currently receiving Arikayce

    Approve for the duration noted when BOTH concurrent background multidrug therapy and ONE sputum-culture status criterion are met:

    Continuation MAC therapy

    • Arikayce will be used in conjunction with a background multidrug regimen.
    • ONE sputum-culture status criterion

      • Patient has not achieved negative sputum cultures for Mycobacterium avium complex.Approve for 1 year
      • Patient has achieved negative sputum cultures for Mycobacterium avium complex for less than 12 months.Approve for 1 year total

        Approve enough Arikayce to complete 12 months of therapy following a negative sputum culture.

    Policy Summary
    PayerCigna
    PolicyAntibiotics (Inhaled) - Arikayce
    Policy CodePolicy IP0383
    Change TypeMaterial clinical criteria revision
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and submit documentation supporting the applicable clinical criteria before requesting coverage.
    SourceLink
    On This Page
    Covered Uses and LimitationsCoverage ThresholdsAuthorization, Documentation, and Denial RisksTherapy OverviewClinical DefinitionsInitial TherapyContinuation Therapy
    Prescribed by a pulmonologist, infectious diseases physician, or physician specializing in MAC lung infections
    Therapy after MAC culture conversion
    Maximum treatment period describedComplete 12 months of therapy after the first negative MAC sputum culture
    Continuation durationApprove for 1 year total when negative MAC sputum cultures have been achieved for less than 12 months
    Ongoing culture statusContinuation also applies when the patient has not achieved negative MAC sputum cultures
  1. The MAC isolate is susceptible to amikacin, as documented in the laboratory report.
  2. Arikayce will be used in conjunction with the background multidrug regimen.
  3. The prescription is from a pulmonologist, infectious diseases physician, or physician specializing in treatment of MAC lung infections.
  4. Documentation Required

    Continuation Documentation

    For continuation of Arikayce for MAC lung disease, document ongoing combination therapy and the patient’s current MAC sputum-culture status, including whether cultures remain positive or have been negative and, if negative, the duration of negativity.

    • Arikayce will continue to be used in conjunction with a background multidrug regimen, typically including a macrolide, ethambutol, and a rifamycin.
    • Document whether the patient has achieved negative sputum cultures for MAC.
    • If sputum cultures remain positive, continuation may be approved for 1 year.
    • If sputum cultures have been negative for less than 12 months, continuation may be approved for 1 year total, with enough Arikayce to complete 12 months of therapy following the negative culture.

    Unsupported block type: documentation

    Denial Risk

    Unsupported Diagnosis or Coding

    Claims may be denied as not covered when the submitted service is billed for a diagnosis or condition that is not covered under the policy or is not accompanied by the applicable covered diagnosis or procedure code(s). Providers must use the most appropriate codes in effect on the submission date.

    • Verify that the billed diagnosis supports a covered indication under the policy.
    • Submit the applicable covered diagnosis and procedure code(s) for the service.
    • Services billed without covered code(s), or for an inapplicable condition, are subject to denial as not covered.
    Denial Risk

    Other Uses May Be Denied

    Arikayce for any use other than covered MAC lung disease or cystic fibrosis with documented Pseudomonas aeruginosa is considered not medically necessary and is subject to denial.

    • Covered indications are MAC lung disease meeting the applicable criteria and cystic fibrosis with Pseudomonas aeruginosa in an airway culture.
    • Other uses are not medically necessary under this policy.
    Denial Risk

    Failure to Meet Initial MAC Criteria

    Initial MAC requests are at risk for denial when any required criterion is missing or cannot be documented.

    • Patient is under 18 years of age.
    • Fewer than 6 consecutive months of background multidrug therapy have been completed.
    • A positive MAC sputum culture is not documented after the required background therapy period.
    • The MAC isolate is not documented as susceptible to amikacin.
    • Arikayce is not being used with a background multidrug regimen.
    • The prescriber does not meet the required pulmonology, infectious diseases, or MAC-specialist qualification.
    Denial Risk

    Failure to Meet Cystic Fibrosis Criteria

    Cystic fibrosis requests are at risk for denial when qualifying Pseudomonas aeruginosa documentation or the required prescriber qualification is absent.

    • Pseudomonas aeruginosa is not documented in an airway culture, such as sputum, oropharyngeal, or bronchoalveolar lavage culture.
    • The prescription is not from, or made in consultation with, a pulmonologist or physician specializing in cystic fibrosis treatment.
    The Mycobacterium avium complex isolate is susceptible to amikacin according to the laboratory report.
  5. Arikayce will be used in conjunction with a background multidrug regimen.
  6. Arikayce is prescribed by a pulmonologist, infectious diseases physician, or physician who specializes in the treatment of Mycobacterium avium complex lung infections.
  7. Cystic fibrosis with Pseudomonas aeruginosa

    Approve for 1 year when ALL of the following are met:

    • Patient has Pseudomonas aeruginosa in an airway culture, such as a sputum culture, oropharyngeal culture, or bronchoalveolar lavage culture.
    • Arikayce is prescribed by or in consultation with a pulmonologist or a physician who specializes in the treatment of cystic fibrosis.